Oral Contraceptives May Triple Stroke Risk
New Delhi: Women who use a
combined oral contraceptive
(COC)—better known as the pill—are three times more likely to suffer an unexpected stroke than those who don't. These new findings were presented at a conference of European Stroke Organisation in Finland's Helsinki on May 20.
The pill is a hormonal contraceptive, containing both
oestrogen and progestogen
, which prevents the ovaries from releasing an egg each month. A research at Istanbul University in Turkiye has established the connection between cryptogenic
ischaemic stroke
(CIS) and oral contraceptives. The research analysed 268 women, aged 18 to 49 years, who experienced unexpected strokes, comparing them with 268 women in the similar age group without a stroke history.
Studies from 2019 and 2022 highlighted similar concerns. The discovery of direct vascular effects of COCs requires immediate attention. Healthcare professionals acknowledge that extended usage periods and increased oestrogen levels heighten stroke risks.
Dr Anuradha Kapur, principal director (obstetrics & gynaecology) and head of the unit at Max Smart Super Specialty Hospital, Saket, pointed out that while medicines could notably raise the likelihood of ischaemic strokes, they typically required existing risk elements to cause harm.
"Think of it as adding gasoline to a fire that has not yet been lit. If you have a genetic factor or already have a risk factor, the pill can be the trigger," she clarified.
However, research findings demonstrated that the increased stroke risk associated with oral contraceptive use appears to operate independently, as no significant associations were found between contraceptive usage and other documented risk factors.
"Our findings confirm earlier evidence linking oral contraceptives to stroke risk," said Dr Mine Sezgin of the neurology department at Istanbul University and the lead author of the study. "What's particularly notable is that the association remains strong even when accounting for other known risk factors, which suggests there may be additional mechanisms involved—possibly genetic or biological."
Dr Renu Gupta, director of obstetrics and gynaecology at Sri Balaji Action Medical Institute Delhi, emphasised that stroke resulted from multiple factors, including genetic, physiological and lifestyle-related risks.
She noted that COC could trigger complications in women with underlying health conditions, including undiagnosed thrombophilias or autoimmune conditions.
While the researchers note that further prospective studies are needed, they advise clinicians to exercise caution when prescribing the pill to women with known vascular risk factors or a history of ischaemic stroke.
Describing the connection between oral contraceptives and stroke, prof Manjari Tripathi, head of the neurology department at AIIMS, explained that COC usage consistently correlated with increased ischaemic stroke risk, particularly in women with pre-existing health risk factors.
COC usage increases ischaemic stroke risk by 1.6 to 2 times, with higher risks in women experiencing migraines with aura. The risk intensifies for women who smoke, have high blood pressure, migraines with aura, or a stroke history.
The oestrogen component potentially increases blood coagulability and clot formation.
Dr Vinit Suri, senior consultant of neurology at Indraprastha Apollo Hospitals, noted that first-year usage presented the highest risk, affected by oestrogen dosage.
Modern pills contain lower oestrogen levels, reducing risks compared to older formulations, he pointed out. Risk increases with smoking, hypertension or age above 35. Healthy young women face minimal absolute risk, with pregnancy presenting higher stroke risks than oral contraceptives.
"The real risk lies in stacking oestrogen on top of other vascular triggers—smoking, uncontrolled hypertension or migraine with aura—where non-oestrogen methods are clearly the wiser bet," said Dr Bhaskar Shukla, consultant neurologist at PSRI Hospital. Informed choice, annual check-ups and the growing menu of highly effective LARC devices mean women no longer have to trade peace of mind for modern contraception, he added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
22-05-2025
- Hans India
Birth control pill may triple risk of cryptogenic stroke in women: Study
New Delhi: Taking birth control pills or combined oral contraceptives containing both oestrogen and progestin may triple the risk of cryptogenic stroke in young women, according to a study. Strokes without a known cause are called cryptogenic. It accounts for up to 40 per cent of all ischaemic strokes in young adults. Despite its prevalence, the contribution of sex-specific risk factors, such as contraceptive use, has remained underexplored. The findings add to a growing body of evidence linking hormonal contraception to vascular risk in women of reproductive age. 'Our findings confirm earlier evidence linking oral contraceptives to stroke risk,' said lead author Dr. Mine Sezgin, Department of Neurology, Istanbul University. 'What's particularly notable is that the association remains strong even when accounting for other known risk factors, which suggests there may be additional mechanisms involved – possibly genetic or biological,' she added. The research included 268 women aged 18-49 years with cryptogenic ischaemic stroke (CIS) and 268 age-matched stroke-free controls across 14 centres in Europe. Of the participants, 66 patients and 38 controls were using combined combined oral contraceptives. While the researchers note that further prospective studies are needed, they advise clinicians to exercise caution when prescribing combined oral contraceptives to women with known vascular risk factors or a history of ischaemic stroke. 'Our findings should prompt more careful evaluation of stroke risk in young women, particularly those with additional risk factors,' Dr. Sezgin said. Next, the researchers plan to explore biological and genetic mechanisms underlying the observed association between combined oral contraceptive use and increased stroke risk to better understand how hormonal contraceptives may independently elevate stroke risk. The findings were presented at the ongoing European Stroke Organisation Conference (ESOC) 2025 in Helsinki, Finland.
Time of India
22-05-2025
- Time of India
Oral Contraceptives May Triple Stroke Risk
New Delhi: Women who use a combined oral contraceptive (COC)—better known as the pill—are three times more likely to suffer an unexpected stroke than those who don't. These new findings were presented at a conference of European Stroke Organisation in Finland's Helsinki on May 20. The pill is a hormonal contraceptive, containing both oestrogen and progestogen , which prevents the ovaries from releasing an egg each month. A research at Istanbul University in Turkiye has established the connection between cryptogenic ischaemic stroke (CIS) and oral contraceptives. The research analysed 268 women, aged 18 to 49 years, who experienced unexpected strokes, comparing them with 268 women in the similar age group without a stroke history. Studies from 2019 and 2022 highlighted similar concerns. The discovery of direct vascular effects of COCs requires immediate attention. Healthcare professionals acknowledge that extended usage periods and increased oestrogen levels heighten stroke risks. Dr Anuradha Kapur, principal director (obstetrics & gynaecology) and head of the unit at Max Smart Super Specialty Hospital, Saket, pointed out that while medicines could notably raise the likelihood of ischaemic strokes, they typically required existing risk elements to cause harm. "Think of it as adding gasoline to a fire that has not yet been lit. If you have a genetic factor or already have a risk factor, the pill can be the trigger," she clarified. However, research findings demonstrated that the increased stroke risk associated with oral contraceptive use appears to operate independently, as no significant associations were found between contraceptive usage and other documented risk factors. "Our findings confirm earlier evidence linking oral contraceptives to stroke risk," said Dr Mine Sezgin of the neurology department at Istanbul University and the lead author of the study. "What's particularly notable is that the association remains strong even when accounting for other known risk factors, which suggests there may be additional mechanisms involved—possibly genetic or biological." Dr Renu Gupta, director of obstetrics and gynaecology at Sri Balaji Action Medical Institute Delhi, emphasised that stroke resulted from multiple factors, including genetic, physiological and lifestyle-related risks. She noted that COC could trigger complications in women with underlying health conditions, including undiagnosed thrombophilias or autoimmune conditions. While the researchers note that further prospective studies are needed, they advise clinicians to exercise caution when prescribing the pill to women with known vascular risk factors or a history of ischaemic stroke. Describing the connection between oral contraceptives and stroke, prof Manjari Tripathi, head of the neurology department at AIIMS, explained that COC usage consistently correlated with increased ischaemic stroke risk, particularly in women with pre-existing health risk factors. COC usage increases ischaemic stroke risk by 1.6 to 2 times, with higher risks in women experiencing migraines with aura. The risk intensifies for women who smoke, have high blood pressure, migraines with aura, or a stroke history. The oestrogen component potentially increases blood coagulability and clot formation. Dr Vinit Suri, senior consultant of neurology at Indraprastha Apollo Hospitals, noted that first-year usage presented the highest risk, affected by oestrogen dosage. Modern pills contain lower oestrogen levels, reducing risks compared to older formulations, he pointed out. Risk increases with smoking, hypertension or age above 35. Healthy young women face minimal absolute risk, with pregnancy presenting higher stroke risks than oral contraceptives. "The real risk lies in stacking oestrogen on top of other vascular triggers—smoking, uncontrolled hypertension or migraine with aura—where non-oestrogen methods are clearly the wiser bet," said Dr Bhaskar Shukla, consultant neurologist at PSRI Hospital. Informed choice, annual check-ups and the growing menu of highly effective LARC devices mean women no longer have to trade peace of mind for modern contraception, he added.
Time of India
15-05-2025
- Time of India
Gujarat's first centre of competence for sickle cell anaemia gets Centre's nod
Gandhinagar: The state govt announced on Thursday that Gujarat's first centre of competence (CoC) for has been approved by the Union govt. The minister stated that the centre will be set up in Surat at a cost of Rs 6 crore and will serve as a hub for comprehensive patient care, education and research. Tired of too many ads? go ad free now The announcement was made during the launch of the 2047, which was launched on Thursday by PM Narendra Modi. State minister of tribal development Kuber Dindor said that to support this initiative, the Union health and tribal development ministries have allocated a grant of Rs 6 crore. Under this centre, nodal officers, sickle cell anaemia counsellors and healthcare professionals from 14 tribal districts of the state will receive specialised training, Dindor added. Among Gujarat's 14 tribal districts, south Gujarat has the largest tribal population with a high number of affected patients. An official statement said that given the high prevalence of sickle cell disease and a substantial tribal population in south Gujarat, the new civil hospital in Surat has been selected as the site for the CoC. The centre will be equipped with a laboratory for sickle cell patients, along with facilities including 30 treatment beds and two ICU beds. A specialised training centre will be established to facilitate capacity-building programmes for healthcare providers. Additionally, where required, culturally relevant training materials and awareness literature will be developed and disseminated in local tribal languages to enhance communication and outreach, the state govt said. The CoC will play an important role in addressing the challenges of hereditary diseases like sickle cell anaemia, with a focus on providing long-term, sustainable solutions, the statement added. According to the 2011 census figures, there were 8,91,262 patients with sickle cell trait (SCT) and 66,845 patients with sickle cell disease (SCD) in the state. Sickle cell anaemia (also known as sickle cell disorder or sickle cell disease) is a , where the blood cells are sickle-shaped instead of round and haemoglobin is abnormal.
